Biotech and Pharma Market Trends: Q2 2026 Review and Forecast

AI moves from hype to reality

The life science sector is emerging as one of the more credible AI end-use markets, and the technology is quickly becoming a standard operational tool in both biotech and pharma.

AI-driven tools to improve protein folding predictions, identify binding sites and optimize trial design support a clear line of sight to value creation. According to GlobalData, AI deployment is concentrated in areas where returns are most tangible, specifically drug discovery, target identification and clinical trial design.

Thirty-one percent of the 157 biopharmaceutical professionals surveyed for the report said they expect AI to increase R&D productivity by 11 to 20 percent over the next year, while 38 percent anticipate R&D cost reductions due to AI.

That credibility continues drawing tech and pharma companies even deeper into healthtech. In Q2, Amazon (NASDAQ:AMZN) launched its commercial AI drug-discovery platform, Amazon Bio Discovery, built around biological foundation models and lab-in-the-loop workflows to accelerate early stage molecule design and testing.

Further, commentary from the AWS Life Sciences Symposium suggests that the AI push is bringing the tech and health sectors together, highlighting ongoing customer and partner activity from firms including Sanofi (NASDAQ:SNY), Roche Holding (OTCQX:RHHBY,SWX:ROG) subsidiary Genentech and Bristol-Myers Squibb (NYSE:BMY).

Finally, Anthropic’s hiring of John Jumper, the scientist behind AlphaFold at Google, “signals (that) Anthropic … is going to be entering the biotech space in an even more significant manner,” said Shrayer.

If that thesis plays out, AI will cement its role as core infrastructure in pharma and biotech. The potential payoff is immense — Shrayer pointed out that roughly 90 percent of drugs in pipelines fail, meaning that even marginal improvements in success rates can have an impact on returns.

Momentum extends beyond drug discovery and into the operational plumbing of healthcare, as demonstrated by Prosper AI’s announcement of a US$30 million Series A round led by a16z.

With this new funding, the healthcare operations startup, built to automate administrative workflows, plans to expand its engineering teams and deepen integrations with major electronic health record platforms.

Where is the money going?

Oppenheimer's Biotech M&A and BD&L Pulse report characterizes the first half of 2026 as the strongest start to a calendar year for biotech strategic activity since the pandemic. According to researchers at the firm, most of the M&A activity in H1 was concentrated in early stage clinical companies, particularly those in Phase 1.

Clinical-stage small molecule and AI-enabled platforms attracted outsized capital, with upfront payments for platform and discovery-stage deals topping US$3.8 billion, more than double the combined total from the past three years.

Oncology reclaimed the top spot among industry themes, a shift underscored by standout data from companies like Revolution Medicines (NASDAQ:RVMD). Shrayer noted that its pancreatic cancer drug “reportedly received a standing ovation at ASCO” after extending median survival versus chemotherapy alone.

The report also states that cell and gene therapies, especially CAR-T, accounted for a meaningful share of H1 transaction value, underscoring continued investor interest in the space.

According to Shrayer, the backdrop could improve further if US Food and Drug Administration leadership changes continue to translate into a more open stance toward genetic treatments and expedited pathways.

“It just seems like they’re more willing now to put them on an expedited pathway,” he said.

If that posture persists, the next several quarters could see a slate of genetic therapies reach regulators, with corresponding valuation implications; however, another structural headwind for gene-based medicine is cost.

In the case of CRISPR Therapeutics (NASDAQ:CRSP), patient uptake has been slower than hoped due to the sheer complexity and burden of the treatment process.

“I think this is something that you'll see the insurance companies increasingly address,” said Shrayer.

For investors, the evolution of payment models — Shrayer identified staged, outcomes-based payments as one approach — will be crucial. A scalable, regulator-sanctioned template for paying for curative therapies could unlock far broader adoption and support higher, more stable valuations in the gene therapy complex.

“The idea that payment has to be linked toward a sustained benefit makes sense,” he said. "So I could see that model increasingly adopted with genetic treatments.”

Risk-on sentiment ramping up

Big Pharma continues to lean into M&A to refill its pipelines, accounting for about 75 percent of the total US$117 billion in transaction value in the first half of 2026, according to Oppenheimer's data. That deal flow suggests there are still exit routes for earlier-stage platforms, and that deal activity has remained brisk heading into H2.

The initial public offering market is showing some life too, with Oura, the maker of a health-tracking smart ring, confidentially filing for a US listing and expected to go public later this year.

But the macro backdrop still matters; with US interest rate cuts looking unlikely anytime soon, high front-end yields continue to compete with long-duration biotech risk. Those circumstances are keeping the funding environment for speculative biotech uneven, even as the exit market reopens.

As Shrayer put it, “If you can get 5 percent out of a treasury, it’s a lot more palatable when there’s a low interest rate environment to lock the money away on these kinds of more speculative biotech companies.”

For now, sentiment is somewhere between cautious and risk on.

“I think we’re getting a little more risk on; I definitely think the biotech funding environment has been improved, but I don’t think we’re quite back to the level of funding that we were several years ago," he said.

Additionally, Shrayer said a policy overhang that has weighed on drugmakers is, for now, less acute than many feared. Investor anxiety that the US might move aggressively toward European-style drug price negotiations following US President Donald Trump’s 2025 Most Favored Nation (MFN) pricing push is looking less likely in the near term, even if affordability remains a persistent political flashpoint.

“We’ve seen some drug companies say, well, we’re just not going to launch in Europe because we don’t want you benchmarking to lower prices we’re getting in Europe,” Shrayer said. Reuters reported that drug launches in EU markets fell by about 35 percent in the 10 months after Trump’s MFN executive order, and since then the issue has become a broader market access and pricing problem that regulators are now openly examining.

For now, Shrayer’s team is gravitating to names that sit at the nexus of durable demand and emerging innovation, from gene-editing platforms such as Prime Medicine (NASDAQ:PRME), Beam Therapeutics (NASDAQ:BEAM) and CRISPR Therapeutics, to lab and device providers like Abbott Laboratories (NYSE:ABT) or Becton Dickinson and Company (NYSE:BDX:US), and life science tools companies such as Danaher (NYSE:DHR) and Thermo Fisher Scientific (NYSE:TMO).

Companies like this are increasingly viewed as infrastructure plays on biotech activity, akin to the way certain chipmakers are treated in the AI trade. As Shrayer explained, “Danaher is an example of an investment that our firm likes, because we view it as a backbone play on the life sciences sector.”

As funding improves and AI‑enabled research activity scales, those backbone suppliers can offer a more diversified way to express a constructive view on biotech, with less binary trial risk than early stage names.

Ultimately, while the drug-discovery process is inherently volatile, the long-term growth potential remains compelling.